000			01601 a2200493 4500
005			20250512115535.0
264		0	_c19750707
008			197507s 0 0 eng d
022			_a0032-6518
040			_aNLM _beng _cNLM
100	1		_aPembrey, M E
245	0	0	_aPharmacogenetics. _h[electronic resource]
260			_bThe Practitioner _cNov 1974
300			_a647-54 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAcetyltransferases _xbiosynthesis
650	0	4	_aAdministration, Topical
650	0	4	_aAlleles
650	0	4	_aAnalgesics _xadverse effects
650	0	4	_aAnemia, Hemolytic _xchemically induced
650	0	4	_aAnti-Inflammatory Agents _xadverse effects
650	0	4	_aAntimalarials _xadverse effects
650	0	4	_aApnea _xchemically induced
650	0	4	_aBase Sequence
650	0	4	_aDNA
650	0	4	_aGenes
650	0	4	_aGlucocorticoids
650	0	4	_aGlucosephosphate Dehydrogenase Deficiency
650	0	4	_aHeterozygote
650	0	4	_aHomozygote
650	0	4	_aHumans
650	0	4	_aIsoniazid _xadverse effects
650	0	4	_aMalignant Hyperthermia _xgenetics
650	0	4	_aMetabolism, Inborn Errors _xenzymology
650	0	4	_aMixed Function Oxygenases _xbiosynthesis
650	0	4	_aMolecular Biology
650	0	4	_aNeuritis _xchemically induced
650	0	4	_aPharmacogenetics
650	0	4	_aPhenytoin _xadverse effects
650	0	4	_aSuccinylcholine _xadverse effects
650	0	4	_aSulfonamides _xadverse effects
650	0	4	_aSulfones _xadverse effects
773	0		_tThe Practitioner _gvol. 213 _gno. 1277 _gp. 647-54
999			_c4621092 _d4621092